nefrНефрологияNephrology (Saint-Petersburg)1561-62742541-9439Pavlov First Saint-Petersburg State Medical University10.24884/1561-6274-2006-10-1-25-34nefr-431Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEWS AND LECTURESАЛЬДОСТЕРОН, СЕРДЕЧНО-СОСУДИСТАЯ СИСТЕМА И ПОЧКИALDOSTERONE, CARDIOVASCULAR SYSTEM AND KIDNEYSКарабаеваА. Ж.KarabaevaA. Zh.
кафедра нефрологии и диализа факультета последипломного обучения
Санкт-Петербургский государственный медицинский университет им. акад. И.П. ПавловаRussian Federation2006100120061012534Copyright © Карабаева А.Ж., 20062006Карабаева А.Ж.Karabaeva A.Z.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.nephrolog.ru/jour/article/view/431
.
.
альдостеронэпителиальные и неэпителиальные минералкортикоидные рецепторымиокардиальный фиброзэплеренонaldosteroneepithelial and non-epithelial mineralocorticoid receptorsmyocardial fibrosiseplerenonReferencesFoster RH, MacFarlane CH, Bustamante MO. Recent progress in understanding aldosterone secretion. Gen Pharmacol1997; 28: 647-651Foster RH, MacFarlane CH, Bustamante MO. Recent progress in understanding aldosterone secretion. Gen Pharmacol1997; 28: 647-651Fuller PJ. Aldosterone’s effects and mechanism of action. Curr Opin Endocrinol Diabetes 1997; 4: 218-224Fuller PJ. Aldosterone’s effects and mechanism of action. Curr Opin Endocrinol Diabetes 1997; 4: 218-224Karin M. New twists in gene regulation by glucocorticoid receptor: is DNA binding dispensable? Cell1998; 93: 487-490Karin M. New twists in gene regulation by glucocorticoid receptor: is DNA binding dispensable? Cell1998; 93: 487-490Helman SI, Liu X, Baldwin K et al. Time-dependent stimulation by aldosterone of blocker-sensitive ENaCs in A6 epithelia. Am J Physiol Cell Physiol1998; 274: C 947-C 957Helman SI, Liu X, Baldwin K et al. Time-dependent stimulation by aldosterone of blocker-sensitive ENaCs in A6 epithelia. Am J Physiol Cell Physiol1998; 274: C 947-C 957Booth E, Johnson JP, Stockand JD. Aldosterone. Adv Physiol Educ2002; 26: 8-20Booth E, Johnson JP, Stockand JD. Aldosterone. Adv Physiol Educ2002; 26: 8-20Rossier BC. Mechanisms of action of mineralocorticoid hormones. Endocr Res1989; 15: 206-226Rossier BC. Mechanisms of action of mineralocorticoid hormones. Endocr Res1989; 15: 206-226Duprez D, de Buyzere M, Rietzchel ER, Clement DL. Aldosterone and vascular damage. Curr Hypertens Rep2000; 2; 327-334Duprez D, de Buyzere M, Rietzchel ER, Clement DL. Aldosterone and vascular damage. Curr Hypertens Rep2000; 2; 327-334Wehling M. Nongenomic actions of steroid hormones. Trends Endocrinol Metab 1994; 5: 347-353Wehling M. Nongenomic actions of steroid hormones. Trends Endocrinol Metab 1994; 5: 347-353Wehling M, Spes CH, Win N et al. Rapid cardiovascular action of aldosterone in man. J Clin Endocrinol Metab 1998; 83: 3517-3522Wehling M, Spes CH, Win N et al. Rapid cardiovascular action of aldosterone in man. J Clin Endocrinol Metab 1998; 83: 3517-3522Christ M, Douwes K, Eisen C et al. Rapid nongenomic effects of aldosterone on sodium transport in rat vascular smooth muscle cells: involvement of the Na +/H + antiport. Hypertension 1995; 25: 117-123Christ M, Douwes K, Eisen C et al. Rapid nongenomic effects of aldosterone on sodium transport in rat vascular smooth muscle cells: involvement of the Na +/H + antiport. Hypertension 1995; 25: 117-123Wehling M, Neylon CB, Fullerton M et al. Nongenomic effects of aldosterone on intracellular calcium in vascular smooth muscle cells. Circ Res 1995; 76: 973-979Wehling M, Neylon CB, Fullerton M et al. Nongenomic effects of aldosterone on intracellular calcium in vascular smooth muscle cells. Circ Res 1995; 76: 973-979Ebata S, Muto S, Okada K et al. Aldosterone activates Na+/H + exchange in vascular smooth muscle cells by non-genomic and genomic mechanisms. Kidney Int 1999; 56: 1400-1412Ebata S, Muto S, Okada K et al. Aldosterone activates Na+/H + exchange in vascular smooth muscle cells by non-genomic and genomic mechanisms. Kidney Int 1999; 56: 1400-1412Gekle M, Freudinger R, Mildenberger S, Silbernagl S. Rapid actions of aldosterone on cells from renal epithelium: the possible role of EGF-receptor signaling. Steroids 2002; 67: 499–504Gekle M, Freudinger R, Mildenberger S, Silbernagl S. Rapid actions of aldosterone on cells from renal epithelium: the possible role of EGF-receptor signaling. Steroids 2002; 67: 499–504Epstein M. Aldosterone receptor blockade and the role of eplerenone: evolving perspectives. Nephrol Dial Transpl2003; 18: 1984-1992Epstein M. Aldosterone receptor blockade and the role of eplerenone: evolving perspectives. Nephrol Dial Transpl2003; 18: 1984-1992Silvestre JS, Heymes C, Oubenaisso A et al. Activation of cardiac aldosterone production in rat myocardial infarction. Effect of angiotensin II receptor blockade and role in cardiac fibrosis. Circulation 1999; 99: 2694-2701Silvestre JS, Heymes C, Oubenaisso A et al. Activation of cardiac aldosterone production in rat myocardial infarction. Effect of angiotensin II receptor blockade and role in cardiac fibrosis. Circulation 1999; 99: 2694-2701Stier Jr CT, Benter IF, Ahmad S et al. Enalapril prevents stroke and kidney dysfunction in salt-loaded stroke-prone spontaneously hypertensive rats. Hypertension1989; 13:115–121Stier Jr CT, Benter IF, Ahmad S et al. Enalapril prevents stroke and kidney dysfunction in salt-loaded stroke-prone spontaneously hypertensive rats. Hypertension1989; 13:115–121Stier Jr CT, Chander PN, Gutstein WH et al. Therapeutic benefit of captopril in salt-loaded stroke-prone spontaneously hypertensive rats is independent of hypotensive effect. Am J Hypertens1991; 4: 680 – 687Stier Jr CT, Chander PN, Gutstein WH et al. Therapeutic benefit of captopril in salt-loaded stroke-prone spontaneously hypertensive rats is independent of hypotensive effect. Am J Hypertens1991; 4: 680 – 687Weber KT. Aldosterone in congestive hear failure. N Engl J Med2001; 345 1689 – 1697Weber KT. Aldosterone in congestive hear failure. N Engl J Med2001; 345 1689 – 1697Camargo MJ, von Lutterotti N, Campbell Jr WG et al. Control of blood pressure and end-organ damage in maturing saltloaded stroke-prone spontaneously hypertensive rats by oral angiotensin II receptor blockade. J Hypertens1993; 11: 31–40Camargo MJ, von Lutterotti N, Campbell Jr WG et al. Control of blood pressure and end-organ damage in maturing saltloaded stroke-prone spontaneously hypertensive rats by oral angiotensin II receptor blockade. J Hypertens1993; 11: 31–40Stier Jr CT, Adler LA, Levine S, Chander PN. Stroke prevention by losartan in troke-prone spontaneously hypertensive rats. J Hypertens 1993; 11 [Suppl 3]: S37–S42Stier Jr CT, Adler LA, Levine S, Chander PN. Stroke prevention by losartan in troke-prone spontaneously hypertensive rats. J Hypertens 1993; 11 [Suppl 3]: S37–S42Jalil JE, Janicki JS, Pick R, Weber KT. Coronary vascular remodeling and myocardial fibrosis in the rat with renovascular hypertension: response to captopril. Am J ypertens 1991; 4: 51–55Jalil JE, Janicki JS, Pick R, Weber KT. Coronary vascular remodeling and myocardial fibrosis in the rat with renovascular hypertension: response to captopril. Am J ypertens 1991; 4: 51–55Laragh JH, Sealy JE. The renin-angiotensin-aldosterone system in hypertensive disorders: a key to two forms of arteriolar constriction and a possible clue to risk of vascular injury (heart attack and stroke) and prognosis. In: Laragh JH, Brenner BM (eds) Hypertension 1990; Pathophysiology, Diagnosis, and Management. Raven Press, New York, 1329–1348Laragh JH, Sealy JE. The renin-angiotensin-aldosterone system in hypertensive disorders: a key to two forms of arteriolar constriction and a possible clue to risk of vascular injury (heart attack and stroke) and prognosis. In: Laragh JH, Brenner BM (eds) Hypertension 1990; Pathophysiology, Diagnosis, and Management. Raven Press, New York, 1329–1348Rossi GP, Sachetto A, Visentin P et al. Changes in left ventricular anatomy and function in hypertension and primary aldosteronism. Hypertension 1996; 27: 1039–1045Rossi GP, Sachetto A, Visentin P et al. Changes in left ventricular anatomy and function in hypertension and primary aldosteronism. Hypertension 1996; 27: 1039–1045Halimi JM, Mimram A. Albuminuria in untreated patients with primary aldosteronism or essential hypertension. J Hypertens 1995; 13: 1801–1802Halimi JM, Mimram A. Albuminuria in untreated patients with primary aldosteronism or essential hypertension. J Hypertens 1995; 13: 1801–1802Takeda R, Matsubara T, Miyamori I et al. Research Committee of Disorders of Adrenal Hormones in Japan. Vascular complications in patients with aldosterone producing adenoma in Japan: comparative study with essential hypertension. J Endocrinol Invest 1995; 18: 370–373Takeda R, Matsubara T, Miyamori I et al. Research Committee of Disorders of Adrenal Hormones in Japan. Vascular complications in patients with aldosterone producing adenoma in Japan: comparative study with essential hypertension. J Endocrinol Invest 1995; 18: 370–373Nishimura M, Uzu T, Fuji T et al. Cardiovascular complications in patients with primary aldosteronism. Am J Kidney Dis 1999; 33: 261–266Nishimura M, Uzu T, Fuji T et al. Cardiovascular complications in patients with primary aldosteronism. Am J Kidney Dis 1999; 33: 261–266Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709–717Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709–717Oberleithner H, Ludwig T, Riethmuller C et al. Human endothelium: target for aldosterone. Hypertension 2004; 43 (5): 952-957Oberleithner H, Ludwig T, Riethmuller C et al. Human endothelium: target for aldosterone. Hypertension 2004; 43 (5): 952-957Arima S, Kohagura K, Xu HL et al. Nongenomic vascular action of aldosterone in glomerular microcirculation. J Am Soc Nephrol 2003; 14 (9): 2255-2253Arima S, Kohagura K, Xu HL et al. Nongenomic vascular action of aldosterone in glomerular microcirculation. J Am Soc Nephrol 2003; 14 (9): 2255-2253Todd-Turla KM, Schnermann J, Fejes-Toth G et al. Distribution of mineralocorticoid and glucocorticoid receptor mRNA along the nephron. Am J Physiol 1993; 264 (5, Pt 2): F 781-F 789Todd-Turla KM, Schnermann J, Fejes-Toth G et al. Distribution of mineralocorticoid and glucocorticoid receptor mRNA along the nephron. Am J Physiol 1993; 264 (5, Pt 2): F 781-F 789Komel L. Colocalisation of 11β-hydroxysteroid dehydrogenase and mineralocorticoid receptors in cultured vascular smooth muscle cells. Am J Hypertens 1994; 7 (2): 100-103Komel L. Colocalisation of 11β-hydroxysteroid dehydrogenase and mineralocorticoid receptors in cultured vascular smooth muscle cells. Am J Hypertens 1994; 7 (2): 100-103Jucknevicius I, Segal Y, Kren S et al. Effect of aldosterone on renal transforming growth factor-beta. Am J Physiol 2004; 286 (6): F 1059-F 1062Jucknevicius I, Segal Y, Kren S et al. Effect of aldosterone on renal transforming growth factor-beta. Am J Physiol 2004; 286 (6): F 1059-F 1062Krug AW, Grossmann C, Schuster C et al. Aldosterone stimulates epidermal growth factor receptor expression. J Biol Chem 2003; 278 (44): 4360-4366Krug AW, Grossmann C, Schuster C et al. Aldosterone stimulates epidermal growth factor receptor expression. J Biol Chem 2003; 278 (44): 4360-4366Wehling M. Looking beyond the dogma of genomic steroid action: insights and facts of the 1990s. J Mol Med 1995; 73: 439-447Wehling M. Looking beyond the dogma of genomic steroid action: insights and facts of the 1990s. J Mol Med 1995; 73: 439-447Eddy AA. Plasminogen activator inhibitor-1 and the kidney. Am J Physiol 2002; 283 (20): F 209-F 223Eddy AA. Plasminogen activator inhibitor-1 and the kidney. Am J Physiol 2002; 283 (20): F 209-F 223Lai LJ, Gu Y, Chen J et al. Production of aldosterone by rat mesangial cell and accumulation of extracellular matrix induced by aldosterone. Zhounghua Yi Xu 2003; 83 (21): 1900-1905Lai LJ, Gu Y, Chen J et al. Production of aldosterone by rat mesangial cell and accumulation of extracellular matrix induced by aldosterone. Zhounghua Yi Xu 2003; 83 (21): 1900-1905Nishiyama A, Abe Y. Aldosterone and renal injury. Folia Pharmacol Jap2004; 124 (2): 101-109Nishiyama A, Abe Y. Aldosterone and renal injury. Folia Pharmacol Jap2004; 124 (2): 101-109Epstein M. Aldosterone as a mediator of progressive renal disease: Pathogenetic and clinical implications.Am J Kidney Dis 2001; 37: 677-688Epstein M. Aldosterone as a mediator of progressive renal disease: Pathogenetic and clinical implications.Am J Kidney Dis 2001; 37: 677-688Anderson S, Rennke HG, Brenner BM. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest1986; 77: 1993-2000Anderson S, Rennke HG, Brenner BM. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest1986; 77: 1993-2000Ritz E, Orth S, Weinreich T, Wagner J. Systemic hypertension versus intraglomerular hypertension in progression. Kidney Int1994; 45: 438-442Ritz E, Orth S, Weinreich T, Wagner J. Systemic hypertension versus intraglomerular hypertension in progression. Kidney Int1994; 45: 438-442Meyer TW, Anderson S, Rennke HG, Brenner BM. Reversing glomerular hypertension stabilizes established glomerular injury. Kidney Int1987; 31: 752-759Meyer TW, Anderson S, Rennke HG, Brenner BM. Reversing glomerular hypertension stabilizes established glomerular injury. Kidney Int1987; 31: 752-759The GISEN Study Group: Randomized placebo-controlled trial of effect of ramipril on decline in GFR and risk of terminal renal failure in proteinuric, nondiabetic nephropathy. The GISEN Group. Lancet1997; 349: 1857-1863The GISEN Study Group: Randomized placebo-controlled trial of effect of ramipril on decline in GFR and risk of terminal renal failure in proteinuric, nondiabetic nephropathy. The GISEN Group. Lancet1997; 349: 1857-1863Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329: 1456-1462Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329: 1456-1462Greene E, Kren S, Hostetter TH. Role of aldosterone in the remnant kidney model in the rat. J Clin Invest 1996; 98: 1063-1068Greene E, Kren S, Hostetter TH. Role of aldosterone in the remnant kidney model in the rat. J Clin Invest 1996; 98: 1063-1068Berl T, Katz FH, Henrich WL, de Torrente A, Schrier RW. Role of aldosterone in the control of sodium excretion in patients with advanced chronic renal failure. Kidney Int1978; 14: 228-235Berl T, Katz FH, Henrich WL, de Torrente A, Schrier RW. Role of aldosterone in the control of sodium excretion in patients with advanced chronic renal failure. Kidney Int1978; 14: 228-235Hene RJ, Boer P, Koomans HA, Dorhout Mees EJ. Plasma aldosterone concentrations in chronic renal disease. Kidney Int 1982; 21: 98-101Hene RJ, Boer P, Koomans HA, Dorhout Mees EJ. Plasma aldosterone concentrations in chronic renal disease. Kidney Int 1982; 21: 98-101Quan ZY, Walser M, Hill GS. Adrenalectomy ameliorates ablative nephropathy in the rat independently of corticosterone maintenance level. Kidney Int 1992; 41: 326-333Quan ZY, Walser M, Hill GS. Adrenalectomy ameliorates ablative nephropathy in the rat independently of corticosterone maintenance level. Kidney Int 1992; 41: 326-333Conn JW, Knopf RF, Nesbit RM. Clinical characteristics of primary aldosteronism from an analysis of 145 cases. Am J Surg 1964; 107: 159-172Conn JW, Knopf RF, Nesbit RM. Clinical characteristics of primary aldosteronism from an analysis of 145 cases. Am J Surg 1964; 107: 159-172Rovner DR, Conn JW, Knopf RF et al. Nature of renal escape from the sodiumretaining effect of aldosterone in primary aldosteronism and in normal subjects. J Clin Endocrinol Metab1965; 25: 53-64Rovner DR, Conn JW, Knopf RF et al. Nature of renal escape from the sodiumretaining effect of aldosterone in primary aldosteronism and in normal subjects. J Clin Endocrinol Metab1965; 25: 53-64Rocha R, Chander PN, Khanna K et al. Mineralocorticoid blokade reduces vascular injury in strokeprone hypertensive rats. Hypertension 1998; 31: 451-458Rocha R, Chander PN, Khanna K et al. Mineralocorticoid blokade reduces vascular injury in strokeprone hypertensive rats. Hypertension 1998; 31: 451-458Brown NJ, Kim KS, Chen YQ et al. Synergistic effect of adrenal steroids and angiotensin II on plasminogen activator inhibitor-1 production. J Clin Endocrinol Metab 2000; 85: 336-344Brown NJ, Kim KS, Chen YQ et al. Synergistic effect of adrenal steroids and angiotensin II on plasminogen activator inhibitor-1 production. J Clin Endocrinol Metab 2000; 85: 336-344Brown NJ, Nakamura S, Ma L et al. Aldosterone stimulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo. Kidney Int 2000; 58: 1219-1227Brown NJ, Nakamura S, Ma L et al. Aldosterone stimulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo. Kidney Int 2000; 58: 1219-1227Sun Y, Zhang J, Zhang JQ, Ramires FJ. Local angiotensin II and transforming growth factorbeta 1 in renal fibrosis of rats. Hypertension 2000; 35: 1078-1084Sun Y, Zhang J, Zhang JQ, Ramires FJ. Local angiotensin II and transforming growth factorbeta 1 in renal fibrosis of rats. Hypertension 2000; 35: 1078-1084Кузьмин ОБ, Пугаева МО, Бучнева НВ. Блокада почечных минералкортикоидных рецепторов: новый подход к нефропротективной терапии гипертензивных больных с хронической болезнью почек. Нефрология 2005; 9 (1) 19-24Кузьмин ОБ, Пугаева МО, Бучнева НВ. Блокада почечных минералкортикоидных рецепторов: новый подход к нефропротективной терапии гипертензивных больных с хронической болезнью почек. Нефрология 2005; 9 (1) 19-24Young M, Fullerton M, Dilley R, Funder J. Mineralocorticoids, hypertension and cardiac fibrosis. J Clin Invest 1994; 93: 2578-2583Young M, Fullerton M, Dilley R, Funder J. Mineralocorticoids, hypertension and cardiac fibrosis. J Clin Invest 1994; 93: 2578-2583Brilla CG, Matsubara LS, Weber KT. Antifibrotic effects of spironolactone in prevenring myocardial fibrosis in systemic arterial hypertension. Am J Cardiol 1993; 71: 12A-16ABrilla CG, Matsubara LS, Weber KT. Antifibrotic effects of spironolactone in prevenring myocardial fibrosis in systemic arterial hypertension. Am J Cardiol 1993; 71: 12A-16ASchiffrin EL, Franks DJ, Gutkowska J. Effect of aldosterone on vascular angiotensin II reseptors in the rat. Can J Physiol Pharmacol 1985; 63: 1522-1527Schiffrin EL, Franks DJ, Gutkowska J. Effect of aldosterone on vascular angiotensin II reseptors in the rat. Can J Physiol Pharmacol 1985; 63: 1522-1527Weber KT, Anversa P, Armstrong PW et al. Remodeling and reparation of the cardiovascular system. J Am Coll Cardiol 1992; 20: 316Weber KT, Anversa P, Armstrong PW et al. Remodeling and reparation of the cardiovascular system. J Am Coll Cardiol 1992; 20: 316Rocha R, MartinBerger CL, Yang P et al. Selective aldosterone blockade prevents angiotensin II/saltinduced vascular inflammation in the rat heart. Endocrinology2002; 143: 4828-4836Rocha R, MartinBerger CL, Yang P et al. Selective aldosterone blockade prevents angiotensin II/saltinduced vascular inflammation in the rat heart. Endocrinology2002; 143: 4828-4836Brown NJ, Vaughan DE, Fogo AB. The reninangiotensin aldosterone system and fibrinolysis in progressive renal disease. Semin Nephrol2002; 22: 399-406Brown NJ, Vaughan DE, Fogo AB. The reninangiotensin aldosterone system and fibrinolysis in progressive renal disease. Semin Nephrol2002; 22: 399-406Brown NJ, Agirbasli MA, Williams GH et al. Effect of activation and inhibition of the reninangiotensin system on plasma PAII. Hypertension 1998; 32: 965-971Brown NJ, Agirbasli MA, Williams GH et al. Effect of activation and inhibition of the reninangiotensin system on plasma PAII. Hypertension 1998; 32: 965-971Brown NJ, Vaughan DE, Fogo AB. Aldosterone and PAI – 1: implications for renal injury. J Nephrol 2002; 15 (3): 230-235Brown NJ, Vaughan DE, Fogo AB. Aldosterone and PAI – 1: implications for renal injury. J Nephrol 2002; 15 (3): 230-235Weber К.Т., Brilla С.G. Pathological hypertrophy and cardiac interstitium: fibrosis and reninangiotensinaldosterone system. Circulation 1991; 83: 1849-1865Weber К.Т., Brilla С.G. Pathological hypertrophy and cardiac interstitium: fibrosis and reninangiotensinaldosterone system. Circulation 1991; 83: 1849-1865Weber К.Т., Brilla С.G., Camphell S.E. et al. Pathological hypertrophy with fibrosis: the structural basis for myocardial failure. Blood Pressure1992, 1: 75-85Weber К.Т., Brilla С.G., Camphell S.E. et al. Pathological hypertrophy with fibrosis: the structural basis for myocardial failure. Blood Pressure1992, 1: 75-85Jeunemaitre X, Chatellier G, KreftJais C et al. Efficacy and tolerance of spironolactone in essential hypertension. Am J Cardiol 1987; 60: 820-825Jeunemaitre X, Chatellier G, KreftJais C et al. Efficacy and tolerance of spironolactone in essential hypertension. Am J Cardiol 1987; 60: 820-825de Gasparo M, Whitebread SE, Preiswerk G et al. Antialdosterones: incidence and prevention of sexual side effects. J Steroid Biochem 1989; 32: 223-227de Gasparo M, Whitebread SE, Preiswerk G et al. Antialdosterones: incidence and prevention of sexual side effects. J Steroid Biochem 1989; 32: 223-227Delyani J, Myles K, Funder J et al. Eplerenone (SC 66110), a highly selective aldosterone antagonist. Am J Hypertens1998; 11: 94A.Delyani J, Myles K, Funder J et al. Eplerenone (SC 66110), a highly selective aldosterone antagonist. Am J Hypertens1998; 11: 94A.Rocha R, Chander P, Zuckerman A et al. Role of mineralocorticoids in renal injury in strokeprone hypertensive rats. Hypertension1998; 32: 598Rocha R, Chander P, Zuckerman A et al. Role of mineralocorticoids in renal injury in strokeprone hypertensive rats. Hypertension1998; 32: 598Blasi ER, Rocha R, Rudolph AE, et al. Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int2003; 63: 1791-1800Blasi ER, Rocha R, Rudolph AE, et al. Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int2003; 63: 1791-1800Lacolley P, Labat C, Pujol A et al. Increased carotid wall elastic modulus and fibronectin in aldosteronesalttreated rats: effects of eplerenone. Circulation2002; 106: 2848-2853Lacolley P, Labat C, Pujol A et al. Increased carotid wall elastic modulus and fibronectin in aldosteronesalttreated rats: effects of eplerenone. Circulation2002; 106: 2848-2853Rocha R, Rudolph AE, Frierdich GE et al. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol2002; 83: H 1802-1810Rocha R, Rudolph AE, Frierdich GE et al. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol2002; 83: H 1802-1810Delyani JA, Robinson EL, Rudolph AE. Effect of a selective aldosterone receptor antagonist in myocardial infarction. Am J Physiol Heart Circ Physiol2001; 281: H647-654Delyani JA, Robinson EL, Rudolph AE. Effect of a selective aldosterone receptor antagonist in myocardial infarction. Am J Physiol Heart Circ Physiol2001; 281: H647-654Rajagopalan S, Duquaine D, King S et al. Mineralocorticoid receptor antagonism in experimental atherosclerosis. Circulation 2002; 105: 2212-2226Rajagopalan S, Duquaine D, King S et al. Mineralocorticoid receptor antagonism in experimental atherosclerosis. Circulation 2002; 105: 2212-2226Ward M, Kanellakis P, Ramsey D. Eplerenone suppresses constrictive remodeling and collagen accumulation after angioplasty in porcine coronary arteries. Circulation 2001;104: 467-472Ward M, Kanellakis P, Ramsey D. Eplerenone suppresses constrictive remodeling and collagen accumulation after angioplasty in porcine coronary arteries. Circulation 2001;104: 467-472Suzuki G, Morita H, Mishima T, et al. Effects of long term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure. Circulation 2002; 106: 2967-72Suzuki G, Morita H, Mishima T, et al. Effects of long term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure. Circulation 2002; 106: 2967-72Pitt B, Remme W, Zannad F et al. for the Eplerenone PostAcute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309-1321Pitt B, Remme W, Zannad F et al. for the Eplerenone PostAcute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309-1321Epstein M, Alexander JC, Roniker B. Efficacy and safety of eplerenone, a novel and selective aldosterone receptor antagonist (SARA), in patients with mild to moderate hypertension. Hypertension 1999; 33: 1075Epstein M, Alexander JC, Roniker B. Efficacy and safety of eplerenone, a novel and selective aldosterone receptor antagonist (SARA), in patients with mild to moderate hypertension. Hypertension 1999; 33: 1075Weinberger MH, Roniker B, Krause SL, Weiss RJ. Eplerenone, a selective aldosterone blocker, in mildto moderate hypertension. Am J Hypertens 2002; 15: 709-716Weinberger MH, Roniker B, Krause SL, Weiss RJ. Eplerenone, a selective aldosterone blocker, in mildto moderate hypertension. Am J Hypertens 2002; 15: 709-716Krum H, Nolly H, Workman D et al. Efficacy of eplerenone added to renninangiotensin blockade in hypertensive patients. Hypertension 2002; 40: 117-123Krum H, Nolly H, Workman D et al. Efficacy of eplerenone added to renninangiotensin blockade in hypertensive patients. Hypertension 2002; 40: 117-123Fuller PJ, Young MJ. Mechanisms of mineralocorticoid action. Hypertension2005; 46: 1227-1246Fuller PJ, Young MJ. Mechanisms of mineralocorticoid action. Hypertension2005; 46: 1227-1246
The authors declare that there are no conflicts of interest present.